Immunosuppressive therapy and post-transplant malignancy.
Domhan
Sophie
S
Department of Medicine, Center of Cancer Systems Biology, Caritas St. Elizabeth's Medical Center, Tufts University, 736 Cambridge Street, CBR1, Boston, MA 02135, USA. Sophie.Domhan@Tufts.edu
Zeier
Martin
M
Abdollahi
Amir
A
D001379:Azathioprine / Q000009:adverse effects / Q000494:pharmacology; D065095:Calcineurin Inhibitors; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000494:pharmacology; D009369:Neoplasms / Q000139:chemically induced / Q000209:etiology* / Q000276:immunology; D016377:Organ Transplantation / Q000009:adverse effects; D011409:Propylene Glycols / Q000009:adverse effects / Q000494:pharmacology; D011494:Protein Kinases / Q000502:physiology; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D000068876:Fingolimod Hydrochloride; D009173:Mycophenolic Acid; D001379:Azathioprine; D013110:Sphingosine